Sensipar marketer Amgen Inc. and cinacalcet generic drug sponsors are engaged in a complicated series of launch and litigation moves that are creating uncertainty in the US market for the calcium-sensing receptor agonist and raising new antitrust questions in the process.
A federal judge in Delaware will hear oral argument April 2 on Amgen’s motion for a preliminary injunction to halt Cipla Ltd.'s sale of generic cinacalcet tablets. Cipla commenced...